Social Media Ideas for Pharmaceutical Supply Chain

Supply Chain Menace: Case Study on Pharmaceutical Infiltration!

The pharmaceutical industry plays a pivotal role in safeguarding public health by providing access to safe and effective medicines. However, the increasing complexity of the global...

Reality-based Planning in Pharma: The Key to a High-Performing Supply Chain

Life sciences supply chains are among the most complex in the world. Every day, supply chain leaders must balance shifting demand, constrained supply, and strict regulatory require...

<![CDATA[Pharmaceutical Cold-Chain Logistics: Protecting Integrity from End to End (Aug 2026)]]>

<![CDATA[GS1-certified traceability for DSCSA-ready supply chains]]>

<![CDATA[Implementing a scalable pharmaceutical serialization system]]>

<![CDATA[How Exposed is The U.S. Pharmaceutical Supply Chain to China’s Updated Export Control Regulations?]]>

<![CDATA[Closing U.S. Pharma Supply Chain Gaps: Q&A with Gerren McHam]]>

MOPH Mandates Medicine Tracking System Across Pharmaceutical Supply Chain

The Ministry of Public Health (MOPH) has directed all pharmaceutical manufacturers, importers, distributors, warehouses and pharmaceutical institutions in Qatar to implement a nati...

<![CDATA[Managing the Uncertainty of Inventory, Staffing, and Formulary Planning Around Peptides?]]>

Invisible Work of Rare Pharmacy Delivers Highly Visible Patient Outcomes

Invisible Work of Rare Pharmacy Delivers Highly Visible Patient Outcomes Anonymous (not verified) Fri, 08/21/2026 - 06:38 pharmagather item url Invisible W...

<![CDATA[DSCSA Serialization Checklist]]>

Black Book: Healthcare Supply Chain IT Enters a 2027 Replacement Supercycle as 71% Plan Major Upgrades

Nine in ten surveyed healthcare leaders rank supply chain among their top three non-labor financial levers, while 74% require measurable value from new platforms within 12 months

<![CDATA[What GS1 Certification Means for DSCSA (and why it matters)]]>

Black Book: 2027 Budgets Pivot to Healthcare Supply Chain Control Towers and Outcome-Based Managed Services

Seventy-six percent expect orchestration to become a funded strategic priority by 2028 as supplier-risk transparency, substitution automation and service accountability move into b...

Direct-to-Patient: Transforming the Manufacturer Access Model

Today's guest post comes from Chip Parkinson, CEO at Gifthealth. Chip discusses how Direct-to-Patient (DTP) models can transform the manufacturer access model for prescription...

Should You Centralize Cold Chain Fulfillment? Only If You’ve Solved Distribution First

Cold chain is a logistics problem — not just a throughput problem. Pharmacies must rethink their strategy, not just automate it.  The post Should You Centralize Cold Chain Fulfillm...

Value Drug Company Ready to Support Independent Pharmacies Seeking a New Wholesale Distribution Partner

Pennsylvania-based full-line wholesaler offers transition assistance, transparent pricing and regional gatherings for pharmacy owners affected by changes at Smith Drug Company

<![CDATA[Amazon Pharmacy Launches GLP-1 Delivery Service ]]>

[Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical Services

This podcast explores how clinical trial supplies move from early planning to global delivery, ensuring investigational medicines reach patients safely and on time.

Pharmacy Benefit Operations Infrastructure Must Rise to Regulatory Reform Standards

The PBM reform efforts are directional, not temporary. Meeting these expectations requires automated systems that can reconstruct claim logic on demand and provide real-time alignm...

Direct-to-Consumer Shouldn't Always Mean Direct-To-Mail-Order: Why Fulfillment Choice Matters

Today's guest post comes from Divya Iyer, SVP, Head of Revenue, Pharma Direct at GoodRx. Divya examines why direct-to-consumer strategies shouldn't default to mail-order as the en...

DHA Taps Accenture Federal for Sole-Source Drug Supply Chain Assessment

The active ingredients behind the military’s top 25 combat-essential drugs come almost entirely from foreign sources Accenture will vet onshoring proposals, test manufacturing feas...

<![CDATA[The New Pharma Visibility Journey]]>

The Private Label Biosimilar Paradox in Medicare Part D

By Tyler Novotny and Bryce Platt PBM-affiliated private label biosimilars would seem to have a built-in formulary advantage. But for ustekinumab, that advantage has not carrie...